Advertisement
New Zealand markets closed
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NZD/USD

    0.5980
    -0.0025 (-0.42%)
     
  • NZD/EUR

    0.5528
    -0.0015 (-0.27%)
     
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    82.47
    +1.12 (+1.38%)
     
  • GOLD

    2,228.40
    +15.70 (+0.71%)
     
  • NASDAQ

    18,268.55
    -12.29 (-0.07%)
     
  • FTSE

    7,959.98
    +28.00 (+0.35%)
     
  • Dow Jones

    39,776.29
    +16.21 (+0.04%)
     
  • DAX

    18,497.64
    +20.55 (+0.11%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • NZD/JPY

    90.3950
    -0.3850 (-0.42%)
     

Johnson & Johnson’s Revenue Estimates for 4Q17

Johnson & Johnson’s Revenue Estimates for 4Q17

As we saw in Part 1 of this series, Johnson & Johnson (JNJ) is expected to report a 10.9% growth in revenue to $20.1 billion in 4Q17 compared to 4Q16. The above chart compares the actual revenues for Johnson & Johnson since 1Q16 and estimates for 4Q17. In 4Q17, the segment is expected to report growth in operating revenues, with a favorable impact from foreign exchange.